Progeria research opens new doors to aging and heart disease
A rare disease that makes children age decades too fast is teaching scientists about normal aging. Researchers gathered in October 2025 to review the latest findings.
Hutchinson-Gilford progeria syndrome (HGPS) is an extremely rare genetic condition. Children with progeria age biologically at a rapid rate and die on average at age 14, usually from a heart attack or stroke. The disease is caused by a mutation in the gene encoding a protein called progerin, a damaged form of lamin A, which normally acts as a structural component of the cell nucleus.
In October 2025, the Progeria Research Foundation held its 12th International Scientific Workshop. Researchers discussed new developments in the search for treatments. The meeting report was published in the journal Nature Aging.
Heart and blood vessels as a central theme
A prominent theme was the connection between progeria and ordinary cardiovascular disease. The vascular damage seen in children with HGPS resembles accelerated versions of processes that occur in normal aging. Researchers hope that insights from HGPS can help develop new therapies for older adults with cardiovascular conditions.
Discussions also covered progeroid syndromes more broadly, a group of conditions in which aging is accelerated due to genetic errors. These conditions serve as a kind of laboratory for aging biology, showing in concentrated form what can go wrong in cells as they age.
What this means for normal aging
The scientific value of progeria research lies in the magnifying effect the disease provides. Processes that unfold over decades in healthy people are visible in progeria patients during childhood. That makes it easier to study and test mechanisms. Whether the identified targets will lead to effective therapies for the general population remains uncertain. The workshop report identifies this as a priority for future research.